Dundee firm Exscientia, which specializes in artificial intelligence (AI)-driven drug discovery, said it agreed a strategic research collaboration and licence option agreement with Sanofi in the area of metabolic disease that could be worth up to €250 million.

Exscientia CEO Andrew Hopkins said: ”We are delighted that Sanofi is engaging with Exscientia in a comprehensive, end-to-end drug discovery project.

“This agreement highlights Exscientia’s ability to apply bispecific drug design in a comprehensive and highly productive manner.

“Sanofi has put together an excellent experimental backbone for this collaboration and we look forward to delivering high-value projects for the company.”